Utah Patent of the Month – February 2021
Most testosterone based pharmaceuticals use dose titration schemes to space out the medicine and ensure patients are treated safely. These help as patients absorb and metabolize testosterone at different rates so administering uniform doses are not possible. Lipocine INC. has been designing a new oral testosterone therapy (TT) regimen which does not require dose titrations.
The oral TT is a fixed dose which can be taken once or twice a day as prescribed. The addition of biomarkers are used to track testosterone levels so that, should an unacceptably high level be reached, dosage can be discontinued quickly.They found that a fixed dose within the range of 750-1150 mg per day of a specific testosterone ester allowed for safe and effective TT. With a single or dual oral dose, patients will have easier medication regimens and better treatment strategies in place.
Lipocine is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. They improve compliance, absorption, and more with our proprietary drug delivery technologies.
Are you developing new technology? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.